Dynavax Technologies
CA - Emeryville
BiotechnologyFocus: Synthetic oligonucleotides vaccines, adjuvants
Dynavax Technologies is a life sciences company focused on Synthetic oligonucleotides vaccines, adjuvants.
VaccinesInfectious Diseases
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
0
Pipeline & Clinical Trials
HEPLISAV
Chronic Kidney DiseaseClinical Trials (1)
NCT01282762Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
N/AHEPLISAV-B
PregnantClinical Trials (1)
NCT03664648DV2-HBV-27: Observational Pregnancy Registry
N/AAdjuvanted Hepatitis B Vaccine
Hepatitis B VirusClinical Trials (1)
NCT04385524Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
N/ABG505 SOSIP.664 gp140
HIV InfectionsClinical Trials (1)
NCT04177355Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
Phase 1SD-101
HealthyClinical Trials (1)
NCT00599001Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
Phase 11018 ISS immunostimulatory oligonucleotide with HBV surface antigen
Hepatitis BClinical Trials (1)
NCT00426712Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
Phase 1DV-601
Hepatitis B, ChronicClinical Trials (1)
NCT01023230A Study to Assess DV-601 in Subjects With Chronic Hepatitis B
Phase 11018 ISS immunostimulatory oligonucleotide
Colorectal NeoplasmsClinical Trials (1)
NCT00403052A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT03326752Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Phase 1Phase 1
Clinical Trials (1)
NCT03934736HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
Phase 1SD-101
Chronic Hepatitis CClinical Trials (1)
NCT00823862Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Phase 1Nivolumab
Metastatic Pancreatic AdenocarcinomaZ-1018
ShinglesClinical Trials (1)
NCT05245838Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
Phase 1HEPLISAV
Hepatitis BClinical Trials (1)
NCT01999699A Study of the Immune Response to Heplisav in Healthy Older Adults
Phase 1SD-101
Metastatic MelanomaZ-1018
ShinglesClinical Trials (1)
NCT06569823Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
Phase 1/2SD-101
B-cell LymphomaClinical Trials (1)
NCT02266147Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Phase 1/21018 ISS-HBsAg-Single
Hepatitis BClinical Trials (1)
NCT00498212A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
Phase 2rF1V-1018
Plague, PneumonicClinical Trials (1)
NCT05506969Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2Clinical Trials (1)
NCT07207408Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Phase 2Rituxan
Non-Hodgkin's LymphomaClinical Trials (1)
NCT00251394Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Phase 2HEPLISAV
Hepatitis BClinical Trials (1)
NCT00511095Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
Phase 2Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
Rhinitis, Allergic, SeasonalClinical Trials (1)
NCT00387738Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
Phase 2Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Rhinitis, Allergic, SeasonalClinical Trials (1)
NCT00537355An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
Phase 2HEPLISAV
End Stage Renal DiseaseClinical Trials (1)
NCT01195246Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
Phase 3HEPLISAV-B
Chronic Kidney DiseaseClinical Trials (1)
NCT00985426Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
Phase 3HEPLISAV-B
HIV InfectionClinical Trials (1)
NCT04193189B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
Phase 3HEPLISAV and/or Placebo
HealthyClinical Trials (1)
NCT01005407Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
Phase 3HEPLISAV
HealthyClinical Trials (1)
NCT02117934Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
Phase 3HEPLISAV and/or Placebo
Hepatitis BClinical Trials (1)
NCT00435812Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2024
Portfolio: 28 clinical trials
Top TAs: Infectious Diseases, Nephrology, Oncology
Therapeutic Area Focus
Marketed
Pipeline
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles